Araştırma Çıktıları | WoS | Scopus | TR-Dizin | PubMed
Permanent URI for this communityhttps://hdl.handle.net/20.500.14719/1741
Browse
4 results
Search Results
Publication Metadata only Sex matters in CSU: Women face greater burden and poorer urticaria control, especially in midlife-CURE insights(WILEY, 2025) Kocaturk, Emek; Salameh, Pascale; Asero, Riccardo; Bizjak, Mojca; Gimenez-Arnau, Ana; Grattan, Clive; Pesque, David; Planella-Fontanillas, Nidia; Herzog, Leonie Shirin; Buttgereit, Thomas; Bonnekoh, Hanna; Fomina, Daria; Kovalkova, Elena; Lebedkina, Marina; Kasperska-Zajac, Alicja; Zajac, Magdalena; Zamlynsk, Mateusz; Kulthanan, Kanokvalai; Tuchinda, Papapit; Khoshkhui, Maryam; Hassanpour, Zohreh; Peter, Jonny; Du-Thanh, Aurelie; Meshkova, Raisa; Abuzakouk, Mohamed; Makris, Michael; Bouillet, Laurence; Bocquet, Alexis; Gregoriou, Stamatios; Thomsen, Simon Francis; Dissemond, Joachim; Staubach, Petra; Bauer, Andrea; Danilycheva, Inna; van Doorn, Martijn; Parisi, Claudio; Metz, Martin; Fluhr, Joachim W.; Zuberbier, Torsten; Weller, Karsten; Kolkhir, Pavel; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Bahcesehir University; Lebanese American University; University of Nicosia; University Clinic Golnik; Pompeu Fabra University; Hospital del Mar Research Institute; Hospital del Mar; Sechenov First Moscow State Medical University; Astana Medical University; Medical University of Silesia; Mahidol University; Mashhad University of Medical Sciences; Ahvaz Jundishapur University of Medical Sciences (AJUMS); University of Cape Town; Universite de Montpellier; Cleveland Clinic Foundation; National & Kapodistrian University of Athens; University Hospital Attikon; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); National & Kapodistrian University of Athens; University of Copenhagen; Copenhagen University Hospital; Bispebjerg Hospital; University of Copenhagen; University of Duisburg Essen; Johannes Gutenberg University of Mainz; Technische Universitat Dresden; Carl Gustav Carus University Hospital; NRC Institute of Immunology FMBA of Russia; Erasmus University Rotterdam; Erasmus MC; Hospital Italiano de Buenos Aires; University of Buenos Aires; University of Buenos Aires HospitalBackground: Chronic spontaneous urticaria (CSU), a disease predominantly affecting females, has limited information available on its differences between females and males of varying ages.Objective To investigate sex differences in age groups regarding disease activity, comorbidities, quality of life (QoL) and treatment patterns in CSU patients. Methods: We analysed Chronic Urticaria Registry (CURE) data, an international real-world registry for patients with chronic urticaria. Patients were recruited via an online platform using a standardized questionnaire. The data were analysed for demographics, age of onset, duration of urticaria, (Urticaria Activity Score [UAS], Urticaria Control Test [UCT], Chronic Urticaria Quality of Life Questionnaire [CU-Q2oL]), family history, systemic symptoms, aggravating factors, comorbidities, smoking and alcohol consumption, laboratory parameters, burden of disease, treatment distribution and response rates, compliance to treatment and adverse events. Comparisons were made among age groups <13, 13-17, 18-30, 31-50, 51-65 and >65 years. Results: Across 4136 CSU patients (from 58 sites across 29 countries), 2994 (72.4%) were female. Statistically significant female predominance started at age 31 (<0.001). Compared with males, females showed higher rates of angioedema (59.6 vs. 51.7%, p < 0.001), systemic symptoms (34.6 vs. 25.4%, p < 0.001), sleep disturbance (38.9 vs. 32.5%, p < 0.001), QoL impairment (CU-Q2oL score 32 vs. 27.7, p < 0.001) and lower rates of urticaria control than males in all medication categories (p < 0.05 for all). Females had more concomitant diseases, including asthma, thyroid disease, obesity, autoimmune disease, gastrointestinal disease and depression (p < 0.05 for all). The disease was especially more burdensome and refractory in females aged 51-65 years than males, evidenced by more angioedema and systemic symptoms, worse QoL, lower UCT scores and more emergency visits (p < 0.05 for all). However, these differences were not prominent in the elderly females (>65 years).Conclusion Compared with males, female CSU patients experience more burdensome disease, which gets worse in midlife.Publication Metadata only Sex matters in CSU: Women face greater burden and poorer urticaria control, especially in midlife-CURE insights(WILEY, 2025) Kocaturk, Emek; Salameh, Pascale; Asero, Riccardo; Bizjak, Mojca; Gimenez-Arnau, Ana; Grattan, Clive; Pesque, David; Planella-Fontanillas, Nidia; Herzog, Leonie Shirin; Buttgereit, Thomas; Bonnekoh, Hanna; Fomina, Daria; Kovalkova, Elena; Lebedkina, Marina; Kasperska-Zajac, Alicja; Zajac, Magdalena; Zamlynsk, Mateusz; Kulthanan, Kanokvalai; Tuchinda, Papapit; Khoshkhui, Maryam; Hassanpour, Zohreh; Peter, Jonny; Du-Thanh, Aurelie; Meshkova, Raisa; Abuzakouk, Mohamed; Makris, Michael; Bouillet, Laurence; Bocquet, Alexis; Gregoriou, Stamatios; Thomsen, Simon Francis; Dissemond, Joachim; Staubach, Petra; Bauer, Andrea; Danilycheva, Inna; van Doorn, Martijn; Parisi, Claudio; Metz, Martin; Fluhr, Joachim W.; Zuberbier, Torsten; Weller, Karsten; Kolkhir, Pavel; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Bahcesehir University; Lebanese American University; University of Nicosia; University Clinic Golnik; Pompeu Fabra University; Hospital del Mar Research Institute; Hospital del Mar; Sechenov First Moscow State Medical University; Astana Medical University; Medical University of Silesia; Mahidol University; Mashhad University of Medical Sciences; Ahvaz Jundishapur University of Medical Sciences (AJUMS); University of Cape Town; Universite de Montpellier; Cleveland Clinic Foundation; National & Kapodistrian University of Athens; University Hospital Attikon; CHU Grenoble Alpes; Communaute Universite Grenoble Alpes; Universite Grenoble Alpes (UGA); National & Kapodistrian University of Athens; University of Copenhagen; Copenhagen University Hospital; Bispebjerg Hospital; University of Copenhagen; University of Duisburg Essen; Johannes Gutenberg University of Mainz; Technische Universitat Dresden; Carl Gustav Carus University Hospital; NRC Institute of Immunology FMBA of Russia; Erasmus University Rotterdam; Erasmus MC; Hospital Italiano de Buenos Aires; University of Buenos Aires; University of Buenos Aires HospitalBackground: Chronic spontaneous urticaria (CSU), a disease predominantly affecting females, has limited information available on its differences between females and males of varying ages.Objective To investigate sex differences in age groups regarding disease activity, comorbidities, quality of life (QoL) and treatment patterns in CSU patients. Methods: We analysed Chronic Urticaria Registry (CURE) data, an international real-world registry for patients with chronic urticaria. Patients were recruited via an online platform using a standardized questionnaire. The data were analysed for demographics, age of onset, duration of urticaria, (Urticaria Activity Score [UAS], Urticaria Control Test [UCT], Chronic Urticaria Quality of Life Questionnaire [CU-Q2oL]), family history, systemic symptoms, aggravating factors, comorbidities, smoking and alcohol consumption, laboratory parameters, burden of disease, treatment distribution and response rates, compliance to treatment and adverse events. Comparisons were made among age groups <13, 13-17, 18-30, 31-50, 51-65 and >65 years. Results: Across 4136 CSU patients (from 58 sites across 29 countries), 2994 (72.4%) were female. Statistically significant female predominance started at age 31 (<0.001). Compared with males, females showed higher rates of angioedema (59.6 vs. 51.7%, p < 0.001), systemic symptoms (34.6 vs. 25.4%, p < 0.001), sleep disturbance (38.9 vs. 32.5%, p < 0.001), QoL impairment (CU-Q2oL score 32 vs. 27.7, p < 0.001) and lower rates of urticaria control than males in all medication categories (p < 0.05 for all). Females had more concomitant diseases, including asthma, thyroid disease, obesity, autoimmune disease, gastrointestinal disease and depression (p < 0.05 for all). The disease was especially more burdensome and refractory in females aged 51-65 years than males, evidenced by more angioedema and systemic symptoms, worse QoL, lower UCT scores and more emergency visits (p < 0.05 for all). However, these differences were not prominent in the elderly females (>65 years).Conclusion Compared with males, female CSU patients experience more burdensome disease, which gets worse in midlife.Publication Metadata only Mucosal angioedema involving the oropharynx signals severe cold urticaria: COLD-CE study insights(WILEY, 2025) Bizjak, Mojca; Fomina, Daria; Peter, Jonny; Gimenez-Arnau, Ana Maria; Pesque, David; Goncalo, Margarida; Aarestrup, Fernando Monteiro; Ahsan, Dalia Melina; Al-Ahmad, Mona; Altrichter, Sabine; Andrenova, Gerelma; Bauer, Andrea; Borzova, Elena; Costa, Celia; Fachini Criado, Roberta; Demir, Semra; Dinevski, Dejan; Ensina, Luis Felipe; Gelincik, Asli; Gotua, Maia; Holm, Jesper Gronlund; Inomata, Naoko; Khoshkhui, Maryam; Klyucharova, Aliya; Kocatuerk, Emek; Kosnik, Mitja; Kulthanan, Kanokvalai; de Souza Lima, Eduardo M.; Lu, Rongbiao; Makris, Michael; Meshkova, Raisa; Pasali, Maria; Paulino, Marisa; Ramon, German Dario; Ritchie, Carla; Rudenko, Michael; Thomsen, Simon Francis; Rodrigues Valle, Solange Oliveira; Wagner, Nicola; Xepapadaki, Paraskevi; Xue, Xiaoyang; Kasperska-Zajac, Alicja; Zhao, Zuotao; Terhorst-Molawi, Dorothea; University Clinic Golnik; University of Ljubljana; Sechenov First Moscow State Medical University; University of Cape Town; University of Cape Town; Pompeu Fabra University; Hospital del Mar Research Institute; Hospital del Mar; Hospital del Mar Research Institute; Hospital del Mar; Autonomous University of Barcelona; Hospital Universitari Vall d'Hebron; Universidade de Coimbra; Centro Hospitalar e Universitario de Coimbra (CHUC); Humboldt University of Berlin; Free University of Berlin; Charite Universitatsmedizin Berlin; Berlin Institute of Health; Kuwait University; Kepler University Hospital; Johannes Kepler University Linz; Technische Universitat Dresden; Carl Gustav Carus University Hospital; Niigata University; Universidade de Lisboa; Hospital Santa Maria; Faculdade de Medicina do ABC; Istanbul University; University of Maribor; Universidade Federal de Sao Paulo (UNIFESP); University of Copenhagen; Copenhagen University Hospital; Bispebjerg Hospital; Yokohama City University; Mashhad University of Medical Sciences; Kazan Federal University; Bahcesehir University; Mahidol University; Sun Yat Sen University; National & Kapodistrian University of Athens; University Hospital Attikon; University of Buenos Aires; University of Buenos Aires Hospital; Hospital Italiano de Buenos Aires; Universidade Federal do Rio de Janeiro; University of Erlangen Nuremberg; National & Kapodistrian University of Athens; Community Health Service Center; Medical University of SilesiaPublication Metadata only Omalizumab dosing patterns and drug survival in adult patients with chronic spontaneous urticaria(WILEY, 2025) Zhang, Ditte Georgina; Nielsen, Mia-Louise; Sorensen, Jennifer Astrup; Naassan, Somaia; Vestergaard, Christian; Kocatuerk, Emek; Ali, Zarqa; Thyssen, Jacob P.; Egeberg, Alexander; Thomsen, Simon Francis; University of Copenhagen; Bispebjerg Hospital; Copenhagen University Hospital; Aarhus University; Free University of Berlin; Humboldt University of Berlin; Charite Universitatsmedizin Berlin; Free University of Berlin; Humboldt University of Berlin; Bahcesehir University; University of Copenhagen; University of CopenhagenBackgroundOmalizumab is an effective treatment for chronic spontaneous urticaria (CSU), but strategies and predictors for guiding long-term management and discontinuation remain limited.ObjectivesTo examine real-world treatment patterns, including dosing modifications and discontinuation, and identify potential predictive factors for these outcomes.MethodsThis was a retrospective, observational, real-life study of adult patients with CSU treated with omalizumab at a Urticaria Center of Reference and Excellence (UCARE) in Copenhagen, Denmark, between May 20, 2015, and April 4, 2024. The Kaplan-Meier estimator was used to visualize time to discontinuation and dose escalation/reduction (using standard label dosing as reference), and Cox-regressions with hazard ratios (HR) were used to investigate potential predictive variables.ResultsOf 430 patients initiated on omalizumab, 139 (32.4%) escalated treatment, 161 (37.5%) reduced treatment, and 90 (21.0%) discontinued treatment directly from the standard dose. The median survival time for dose escalation was 2 years (95% CI: 1.17-3.55), and the strongest predictor was a positive basophil histamine release assay (BHRA) (HR: 2.79, 95% CI: 1.69-4.61). Fast treatment response (HR: 0.50, 95% CI: 0.33-0.75) and higher baseline UCT scores (HR: 0.89, 95% CI: 0.82-0.97) decreased the risk of dose escalation. The median survival time to dose reduction was 1.2 years (95% CI: 0.98-1.49) and was more likely in males (HR: 1.68, 95% CI: 1.13-2.50) and patients with fast treatment response (HR: 1.66, 95% CI: 1.12-2.48). Median survival time to discontinuation (all reasons) of omalizumab was 3 years (95% CI: 2.35-3.64).ConclusionsA considerable proportion of patients with CSU require modifications to the recommended omalizumab dosing regimen. A positive BHRA was the strongest predictor for dose escalation, while male sex and fast treatment response were the strongest predictors for dose reduction. Our study highlights the need for individualized strategies in managing CSU.